Max Klement is an Associate at BGV since January 2019.
Max has prior experience in startups and in larger biotech organizations. At JHL Biotech, a biosimilars and contract manufacturing company, he led the Process Development Team and was a Project Manager for novel and biosimilar biologics. Prior to JHL Biotech, Max was a founding team member at Hummingbird Bioscience where he was a Project Manager for Pharmaceutical and Academic collaborations in gastric and liver cancer. Max holds a Ph.D. from the National University of Singapore as an A*STAR fellow where he worked in the lab of Prof. Miranda Yap on antibody engineering approaches, which culminated in a commercial out-licensing agreement. Max completed his MBA from INSEAD in 2018.